KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBT Margin (2019 - 2025)

Historic EBT Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 36.66%.

  • Esperion Therapeutics' EBT Margin rose 235900.0% to 36.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.47%, marking a year-over-year decrease of 214500.0%. This contributed to the annual value of 1.46% for FY2024, which is 1829600.0% up from last year.
  • As of Q3 2025, Esperion Therapeutics' EBT Margin stood at 36.66%, which was up 235900.0% from 16.25% recorded in Q2 2025.
  • Esperion Therapeutics' EBT Margin's 5-year high stood at 42.29% during Q1 2024, with a 5-year trough of 1140.0% in Q1 2021.
  • Its 5-year average for EBT Margin is 230.12%, with a median of 178.06% in 2023.
  • Per our database at Business Quant, Esperion Therapeutics' EBT Margin skyrocketed by 31326700bps in 2021 and then plummeted by -2462800bps in 2022.
  • Esperion Therapeutics' EBT Margin (Quarter) stood at 448.4% in 2021, then skyrocketed by 33bps to 302.06% in 2022, then surged by 41bps to 178.06% in 2023, then skyrocketed by 83bps to 30.16% in 2024, then fell by -22bps to 36.66% in 2025.
  • Its last three reported values are 36.66% in Q3 2025, 16.25% for Q2 2025, and 63.89% during Q1 2025.